Evidence-Based Compounds for Parkinson's
Parkinson's disease is characterised by dopaminergic neuron loss, alpha-synuclein aggregation, mitochondrial dysfunction, and oxidative stress in the substantia nigra. Research identifies neuroprotective compounds with evidence for supporting dopamine metabolism, reducing neuroinflammation, and mitigating mitochondrial damage as potential adjunct approaches.
This page presents computational analysis of published research from PubMed/NCBI, BindingDB, and Reactome. Rankings are based on BiohacksAI discovery score, pathway overlap, and study count. This is not medical advice — consult a healthcare professional before starting any supplement.
Browse all compounds · Biological pathways · Molecular targets · All conditions
© Organiq Sweden AB · Patent pending EVE-PAT-2026-001